Key Points
- Ansbert Gadicke sold 52,627 shares on Nov. 18 at $0.93 for $48,943.11 and has executed a series of November sales, trimming his stake by 0.96% to 5,428,912 shares valued at about $5.05M.
- Werewolf shares recently traded at $0.81 (down $0.04) with a market cap of $39.37M, a 52‑week range of $0.60–$2.38, a 50‑day MA of $1.54 and a 200‑day MA of $1.33.
- Analysts are mixed but generally positive—one Strong Buy, five Buy and one Sell—giving a consensus rating of “Moderate Buy” and a consensus target price of $7.75; the company reported a Q3 EPS of -$0.36, slightly beating estimates.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 26,411 shares of the stock in a transaction dated Thursday, November 20th. The shares were sold at an average price of $0.89, for a total value of $23,505.79. Following the completion of the transaction, the director directly owned 3,413,127 shares of the company's stock, valued at $3,037,683.03. This represents a 0.77% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.
Luke Evnin also recently made the following trade(s):
- On Wednesday, November 19th, Luke Evnin sold 42,566 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.94, for a total transaction of $40,012.04.
- On Tuesday, November 18th, Luke Evnin sold 33,776 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $31,411.68.
- On Monday, November 17th, Luke Evnin sold 36,621 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $0.95, for a total transaction of $34,789.95.
- On Friday, November 14th, Luke Evnin sold 39,560 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.93, for a total transaction of $36,790.80.
- On Thursday, November 13th, Luke Evnin sold 58,372 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.98, for a total value of $57,204.56.
- On Wednesday, November 12th, Luke Evnin sold 26,101 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.09, for a total value of $28,450.09.
- On Tuesday, November 11th, Luke Evnin sold 35,818 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.14, for a total value of $40,832.52.
- On Monday, November 10th, Luke Evnin sold 31,172 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.18, for a total transaction of $36,782.96.
- On Friday, November 7th, Luke Evnin sold 43,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $1.11, for a total value of $48,784.50.
- On Thursday, November 6th, Luke Evnin sold 34,947 shares of Werewolf Therapeutics stock. The shares were sold at an average price of $1.21, for a total transaction of $42,285.87.
Werewolf Therapeutics Price Performance
HOWL stock traded down $0.04 during trading on Friday, hitting $0.82. The company had a trading volume of 644,797 shares, compared to its average volume of 503,091. The business has a 50 day moving average of $1.54 and a 200 day moving average of $1.33. The firm has a market capitalization of $39.71 million, a price-to-earnings ratio of -0.50 and a beta of 0.72. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics, Inc. has a fifty-two week low of $0.60 and a fifty-two week high of $2.38.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last released its earnings results on Tuesday, November 4th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.39) by $0.03. As a group, research analysts predict that Werewolf Therapeutics, Inc. will post -1.56 earnings per share for the current year.
Analysts Set New Price Targets
A number of research firms recently commented on HOWL. Weiss Ratings reissued a "sell (d-)" rating on shares of Werewolf Therapeutics in a report on Wednesday, October 8th. Zacks Research upgraded Werewolf Therapeutics from a "hold" rating to a "strong-buy" rating in a research report on Thursday, October 16th. Bank of America dropped their price objective on Werewolf Therapeutics from $8.00 to $7.00 and set a "buy" rating on the stock in a research note on Tuesday. JMP Securities decreased their target price on Werewolf Therapeutics from $4.00 to $3.00 and set a "market outperform" rating for the company in a research note on Thursday, August 21st. Finally, Citigroup reiterated a "market outperform" rating on shares of Werewolf Therapeutics in a research report on Wednesday, November 12th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $7.75.
Check Out Our Latest Stock Analysis on HOWL
Institutional Investors Weigh In On Werewolf Therapeutics
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP lifted its holdings in shares of Werewolf Therapeutics by 16.9% during the third quarter. Susquehanna International Group LLP now owns 93,041 shares of the company's stock valued at $183,000 after purchasing an additional 13,439 shares during the last quarter. Citadel Advisors LLC acquired a new stake in Werewolf Therapeutics during the 3rd quarter worth about $304,000. Vanguard Group Inc. lifted its stake in Werewolf Therapeutics by 8.5% during the third quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company's stock valued at $2,774,000 after buying an additional 109,796 shares in the last quarter. Bridgeway Capital Management LLC lifted its stake in Werewolf Therapeutics by 157.7% during the second quarter. Bridgeway Capital Management LLC now owns 102,000 shares of the company's stock valued at $111,000 after buying an additional 62,414 shares in the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Werewolf Therapeutics by 1.2% in the second quarter. Bank of America Corp DE now owns 2,129,024 shares of the company's stock worth $2,321,000 after buying an additional 25,882 shares during the period. 64.84% of the stock is owned by institutional investors and hedge funds.
Werewolf Therapeutics Company Profile
(
Get Free Report)
Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
